## RMD: ResMed Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 2.3% below STRENGTH zone (3.0-6.0%); PEG 1.62 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($240.95)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 9
- **Sentiment:** Neutral (Bullish: 2, Bearish: 1)

**1. Mick Farrell, Chairman and CEO of Resmed, Named Chair of AdvaMed Board of Directors**
- Source: WebWire | 20251215T150943 | Bullish | Relevance: 100%
- AdvaMed, the Medtech Association, has announced that Michael "Mick" Farrell, Chairman and CEO of Resmed Inc., will serve as the next chair of its Board of Directors for a two-year term starting in January 2026. Farrell plans to focus on accelerating patient-first innovation, advancing digital transformation, and expanding global access to medtech. He succeeds Peter J. Arduini of GE HealthCare, who oversaw significant growth and integration for AdvaMed.

**2. ResMed (RMD) Downgraded by Baird, Price Target Lowered to $275 | RMD Stock News**
- Source: GuruFocus | 20251216T122853 | Bearish | Relevance: 100%
- Baird has downgraded ResMed (RMD) from an Outperform rating to Neutral, lowering its price target from $300 to $275. This contrasts with recent analyst activities that maintained or raised ratings for the company. ResMed, a leading respiratory care device company, focuses on sleep apnea treatment and digital health initiatives.

**3. Baird downgrades ResMed stock rating to Neutral on slowing growth**
- Source: Investing.com | 20251216T100828 | Somewhat-Bearish | Relevance: 100%
- Baird downgraded ResMed (NYSE:RMD) from Outperform to Neutral, lowering its price target to $275.00 due to decelerating growth over the past three quarters. The firm noted slowing performance in ResMedâ€™s U.S. masks and other category and expressed caution about increasing competition from private entities like React Health. Despite recent strong Q4 2025 earnings which exceeded forecasts, the downgrade reflects concerns about limiting multiple expansion and potential pricing concessions.

**4. ResMed Inc. $RMD Shares Acquired by Neuberger Berman Group LLC**
- Source: MarketBeat | 20251214T132023 | Bullish | Relevance: 100%
- Neuberger Berman Group LLC significantly increased its stake in ResMed Inc., purchasing an additional 22,431 shares. Other institutional investors also adjusted their positions in the medical equipment provider. Analyst ratings for ResMed are generally positive, with a "Moderate Buy" consensus and an average target price of $299.27.

**5. MASTERINVEST Kapitalanlage GmbH Takes $3.02 Million Position in ResMed Inc. $RMD**
- Source: MarketBeat | 20251214T131023 | Somewhat-Bullish | Relevance: 100%
- MASTERINVEST Kapitalanlage GmbH has acquired a new stake of 11,722 shares, valued at $3.02 million, in ResMed Inc. during the second quarter. Other institutional investors like ICW Investment Advisors LLC and Johnson Investment Counsel Inc. also adjusted their holdings in the medical equipment provider. Analysts have a "Moderate Buy" consensus rating for ResMed, with a target price of $299.27.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 16 ($9.01M) |
| Sells | 17 ($5.01M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 6 |

**Top Holders:**
- Vanguard Group Inc: 13.1% (+1.6%)
- Blackrock Inc.: 8.4% (-1.3%)
- State Street Corpora: 4.5% (-1.0%)
- Bank Of New York Mel: 3.1% (-9.8%)
- Geode Capital Manage: 2.9% (+0.9%)

### Key Risks

1. Insider selling cluster: $5.0M in recent transactions.
2. Elevated short interest (8.2%): bears positioning against stock.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +5.3% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.62 elevated, pricing in significant growth expectations. Forward P/E 21.1x stretched relative to 10% growth. Quality metrics strong (ROE 25%, ROA 14%, margin 27%). Balance sheet: strong liquidity (2.9x), low leverage (D/E 0.36). Institutional flow bullish (3 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $36.9B |
| Beta | 0.87 |
| 52W Range | $199.92 - $293.81 |
| Short Interest | 8.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.62 |
| Forward P/E | 21.1 |
| Current P/E | 23.2 |
| YoY Growth | 10.2% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -3.0% to 2.3% (+5.3% in 5 days), confirming momentum buildup. Below STRENGTH zone by 0.7pp (needs >3.0% for momentum thesis). MRS_5 at 2.3% confirms short-term momentum alignment. Below SMA200 (1.00x), long-term trend not supportive. MACD histogram positive (0.68), confirming momentum. RSI neutral at 51. OFD pattern: -SLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.32% (CS: 52) | Neutral |
| RSI_14 | 50.7 | Neutral |
| MACD Histogram | 0.68 | Bullish |
| vs SMA20 | 1.010x | Above |
| vs SMA50 | 0.984x | Below |
| vs SMA200 | 0.999x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $253.07
- **Stop Loss:** $240.95 (4.8% risk)
- **Target:** $265.19 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 99
- **Position Value:** $25,053.93
- **Portfolio %:** 25.05%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-02-05 (Est: $2.71)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.50 | $2.55 | +2.0% |
| 2025Q2 | $2.48 | $2.55 | +2.8% |
| 2025Q1 | $2.36 | $2.37 | +0.4% |
| 2024Q4 | $2.31 | $2.43 | +5.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*